依赖单一产品、业务或地区

港股IPO招股书披露先例 · 257 家公司,267 项

这类事项指申请人大部分收入来自单一产品、业务线、矿山或项目,或集中于某一地区、客户所处行业。招股书通常在概要、风险因素、业务及财务资料等章节披露相关收入金额、占比及其对毛利率的影响,解释依赖的成因如新客户开发、新型号推出或行业需求增长,并披露拓展其他地区或行业、丰富产品组合、推进在研管线等多元化措施,以分散收入基础。

2026-04-30Application Proof
君绮控股有限公司Junqi Holdings Limited

全部收入来源于台湾单一市场

All of our revenue is derived from our businesses in Taiwan and all of our assets are located in Taiwan.

Financial Information · 第 205 页

Accordingly, our financial condition, results of operations and prospects are, to a material extent, subject to economic, political and legal developments in Taiwan.

Financial Information · 第 205 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-30Prospectus
深圳乐动机器人股份有限公司SHENZHEN LDROBOT CO., LTD01236.HK

收入绝大部分来自视觉感知产品

Revenue from visual perception products accounted for the substantial majority of our total revenue during the Track Record Period.

Summary · 第 10 页

During the Track Record Period, we generated most of our revenue from sales of visual perception products, which increased from RMB274.2 million in 2023 to RMB439.3 million in 2024 and further to RMB606.5 million in 2025.

Financial Information · 第 211 页

As a result, revenue from our visual perception products increased from RMB274.2 million in 2023 to RMB606.5 million in 2025, representing a CAGR of 48.7%.

Business · 第 146 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-27Application Proof

高镍三元前驱体收入占比降至24.5%

In 2023, 2024 and 2025, our revenue generated from new energy material represents 68.7%, 60.0% and 53.8% of our total revenue, respectively, with gross profit margin of 13.2%, 15.6% and 15.6% for the same years.

Financial Information · 第 192 页

During the Track Record Period, we have consistently diversified our product portfolio to form a comprehensive product matrix that provides our customers with more competitive products.

Financial Information · 第 192 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-27Application Proof
重庆千里科技股份有限公司Chongqing Afari Technology Co., Ltd.

汽车及摩托车销售占总收入逾85%

During the Track Record Period, we primarily generated revenue from the manufacturing and sales of automobiles and motorcycles, accounting for over 85% of our total revenue in each year during the Track Record Period.

Summary · 第 1 页

Going forward, as we continue to execute our “AI+Mobility” strategy, we are upgrading our growth engine from traditional vehicle manufacturing and sales to closed-loop “AI+Mobility” solutions that integrate manufacturing, engineering, and model-driven AI development.

Financial Information · 第 233 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-24Application Proof
卡拉罗(中国)传动系统股份有限公司Carraro China Drive Systems Co., Ltd.

工程机械产品收入占比升至69.4%

In 2023, 2024 and 2025, revenue from construction equipment was RMB376.5 million, RMB567.9 million and RMB606.7 million, respectively, accounting for 51.2%, 65.3% and 69.4% of our total revenues in the same years, while revenue from agricultural machinery was RMB270.7 million, RMB242.0 million and RMB220.2 million, respectively, accounting for 36.8%, 27.8% and 25.2% of our total revenues, and revenue from mixed applications and material handling accounted for the remainder.

Financial Information · 第 114 页

Our diversified product portfolio across multiple application markets and applications reduces our dependency on any single end-market, allowing us to capture growth opportunities and balance cyclical fluctuations.

Financial Information · 第 114 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-24Application Proof
美克生能源科技股份有限公司Makesense Energy Technology Co., Limited

DES及其他资产开发贡献约九成收入

DES and other asset development revenue accounted for 79.0%, 66.0%, and 89.1% of our total revenue in 2023, 2024, and 2025, respectively.

Financial Information · 第 164 页

During the Track Record Period, we did not generate revenue from electricity trading service, primarily due to the fact that policy frameworks governing electricity trading service were only progressively established during recent periods.

Business · 第 99 页

While DES asset development has been and may continue to be our largest business line, we will expand the high-margin electricity services to help us achieve profitability.

Financial Information · 第 165 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-22Application Proof
南京领行科技股份有限公司Nanjing Lingxing Technology Co., Ltd.

网约车服务收入占总收入逾九成

In 2023, 2024 and 2025, revenue from ride-hailing services was RMB13,724.8 million, RMB14,906.4 million and RMB16,334.8 million, respectively, accounting for 92.1%, 92.6% and 95.5% of our total revenue in the respective years.

Financial Information · 第 149 页

We endeavor to enhance our business growth and profitability by leveraging our diverse revenue sources.

Financial Information · 第 150 页

We have established a diversified business portfolio, primarily covering vehicle leasing and vehicle sales.

Financial Information · 第 151 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-21Application Proof
佳都科技集团股份有限公司PCI Technology Group Co., Ltd.

企业数字化转型业务贡献约七成收入

During the Track Record Period, intelligent urban rail transit solutions contributed the largest share of our gross profit during the same periods primarily due to its higher gross profit margin, accounting for 63.5%, 68.1% and 54.1% of our total gross profit for the years ended December 31, 2023, 2024 and 2025, respectively.

Summary · 第 2 页

Nonetheless, Enterprise digital transformation solutions was our largest segment in terms of revenue, accounting for 62.1%, 68.7% and 70.9% of our total revenue for the years ended December 31, 2023, 2024 and 2025, respectively.

Summary · 第 2 页

Significant changes in our product and service mix will affect our gross profit margin.

Financial Information · 第 207 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-20Application Proof
武汉帝尔激光科技股份有限公司Wuhan DR Laser Technology Corp., Ltd

收入主要来自光伏激光加工设备销售

We are principally engaged in the R&D, manufacturing, sales and related services of laser machining equipment for high-efficiency photovoltaic cells and modules.

Summary · 第 1 页

Our revenue is primarily generated from the sale of laser machining equipment for photovoltaic cells and modules.

Financial Information · 第 190 页

Our gross profit margin remained stable at 45.8%, 46.3% and 45.5% in 2023, 2024 and 2025, respectively.

Financial Information · 第 190 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-16Application Proof
江苏华盛锂电材料股份有限公司Jiangsu HSC New Energy Materials Co., Ltd.

VC产品收入占比逾六成

During the Track Record Period, we generated a substantial portion of our revenue from the sales of our VC and FEC products.

Summary · 第 3 页

In 2023, 2024 and 2025, our revenue generated from our VC products was RMB328.1 million, RMB343.5 million and RMB580.9 million, respectively, accounting for 62.5%, 68.0% and 66.8% of our total revenue in the same periods, respectively.

Financial Information · 第 171 页

Therefore, downstream market demands for our VC products have a material impact on our overall financial performance.

Financial Information · 第 171 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-15Application Proof
安诺优达基因科技(北京)股份有限公司Annoroad Gene Technology (Beijing) Co., Ltd.

NIPT试剂盒占收入约46%-50%,为最大产品

NIPT kit | 218,637 | 46.1 | 256,780 | 49.6 | 257,549 | 47.1

Summary · 第 3 页

While our IVD test kits are not required to be purchased in bundle with our genetic sequencer or bioinformatics analysis software, hospitals and ICLs who have deployed our genetic sequencer usually prioritize our IVD test kits and their compatible bioinformatics analysis software due to their familiarity with the operational workflow and trust in our brand.

Summary · 第 2 页

We sold 485 CNV-seq kits to 40 customers as of December 31, 2025, with 27 of which were also our NIPT customers, demonstrating the synergy of our different IVD test kits.

Summary · 第 6 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-12Application Proof
宜品营养科技(青岛)集团股份有限公司Yeeper Nutrition Technology (Qingdao) Group Co., Ltd.

羊奶婴幼儿配方奶粉收入占比逾五成

For the years ended December 31, 2023, 2024 and 2025, revenue generated from our goat/sheep milk infant formula products was RMB926.4 million, RMB1,032.7 million, and RMB1,009.4 million, accounting for approximately 57.4% ,58.6%, and 54.2% of our total revenue in the corresponding year, respectively.

Financial Information · 第 228 页

Our core differentiation lies in our commitment to developing low-allergen dairy products, compared to traditional bovine-based formulations.

Financial Information · 第 228 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-10Application Proof
四川好医生云医疗科技集团股份有限公司GOOD DOCTOR CLOUD HEALTHCARE & TECHNOLOGY GROUP CO., LTD.

医药直供及分销服务收入占比近八成

The majority of our revenue in each year during the Track Record Period was derived from our pharmaceutical direct supply and distribution services.

Summary · 第 3 页

For the years ended December 31, 2023, 2024 and 2025, the revenue generated from our pharmaceutical direct supply and distribution services was RMB2,448.5 million, RMB2,527.4 million and RMB3,027.5 million, respectively, accounting for 79.9%, 77.5% and 79.2% of our total revenue for the same years, respectively.

Business · 第 131 页

Our direct-supply model removes unnecessary distribution intermediaries and directly reaches customers, which helps primary healthcare institutions and primary pharmacies reduce procurement costs and enhance their sourcing efficiency.

Business · 第 132 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-09Prospectus
长春长光辰芯微电子股份有限公司Gpixel Changchun Microelectronics Inc.03277.HK

工业成像收入占比升至74.6%,CIS产品收入占92.8%

In 2023, 2024 and 2025, our revenue attributable to sales of CMOS image sensors amounted to RMB505.0 million, RMB510.3 million and RMB794.7 million, respectively, and accounted for approximately 83.5%, 75.8% and 92.8% of our total revenue for the corresponding periods.

Financial Information · 第 230 页

Revenue from industrial imaging solutions amounted to RMB327.5 million in 2023, RMB446.6 million in 2024 and RMB639.0 million in 2025, accounting for 54.2%, 66.3% and 74.6% of our total revenue for the respective periods.

Financial Information · 第 231 页

While our professional photography and video, and medical imaging still contribute relatively small portion of our revenue, we expect these and other specialized imaging applications across high-tech industries will contribute more to our revenue as our market shares in these scenarios increase.

Financial Information · 第 231 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-08Prospectus
思格新能源(上海)股份有限公司Sigenergy Technology Co., Ltd.06656.HK

旗舰产品SigenStor占总收入逾九成

In particular, our revenue growth has been driven by sales of SigenStor, which accounted for more than 90% of our total revenue during the Track Record Period.

Summary · 第 11 页

While we will seek to expand our product portfolio and revenue streams, as our flagship product, we expect that sales from SigenStor will continue to be our primary product and main revenue source, with its compelling value propositions continuing to drive its market acceptance and adoption across residential and C&I application scenarios, especially in overseas markets with end-customer bases with higher demand for high-end, advanced products which can be sold at premium selling prices.

Business · 第 148 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-08Application Proof
清陶(昆山)能源发展集团股份有限公司Qingtao (Kunshan) Energy Development Group Co., Ltd.

收入集中于电池业务且产品结构变动

Our financial performance was materially affected by changes in our product mix during the Track Record Period.

Financial Information · 第 212 页

During the Track Record Period, the contribution of EV batteries and ESS batteries to our total revenue increased, while the contribution of automation equipment decreased.

Financial Information · 第 212 页

Revenue from ESS batteries increased from RMB92.3 million in 2023 to RMB258.4 million in 2024 and further to RMB592.1 million in 2025, respectively.

Financial Information · 第 212 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-07Application Proof
武汉艾米森生命科技股份有限公司Wuhan Ammunition Life-tech Co., Ltd.

收入集中于少数已获批产品,新产品贡献尚小

During the Track Record Period, substantially all of our revenue was generated from the sales of our NMPA-approved products, namely IColocomf (艾長康), IColohunter (艾長健), IEsohunter (艾思寧) and IHepcomf (艾馨甘).

Business · 第 159 页

Our revenue was primarily derived from limited sales of our NMPA-approved products during the Track Record Period.

Financial Information · 第 226 页

Consequently, the contribution of our new products to overall revenue remains modest to date.

Business · 第 164 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-02Application Proof
上海汇伦医药股份有限公司Shanghai Huilun Pharmaceutical Co., Ltd.

收入主要来自核心产品希为纳

During the Track Record Period, we generated revenue primarily from the sales of our key marketed products, represented by Xiweina (希為納^®^), the only domestically developed sivelestat sodium approved in China, and Zuoyu (佐愈^®^), China’s first domestically developed Category II levofolinic acid.

Summary · 第 1 页

During the Track Record Period, we derived the majority of our revenue from sales of Xiweina, the first and only domestically developed sivelestat sodium in China indicated for ALI/ARDS.

Financial Information · 第 217 页

Despite fluctuations in demand during the outbreak and the subsequent ease of COVID-19, Xiweina is well-positioned to capture long-term growth given its exclusive market position, which provides pricing flexibility and creates competitive barriers.

Financial Information · 第 217 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看
2026-04-02Application Proof
浙江毛源昌眼镜股份有限公司Zhejiang Maoyuanchang Eyewear Co., Ltd.

处方眼镜贡献约八成收入

Prescription spectacles is the highest revenue contribution throughout the Track Record Period representing about 79.9% of our revenue for the years ended 31 December 2023, 2024 and 2025, respectively. The gross profit margin of prescription spectacles during the Track Record Period were 61.2%, 59.8% and 62.4% for the years ended 31 December 2023, 2024 and 2025, respectively. The fluctuation was primarily a result of our product and pricing policy shift discussed above.

Financial Information · 第 208 页

Our revenue growth and customer retention and conversion rate depend on our ability to improve our capacity to offer a comprehensive range of vision solutions that address diverse needs and price points.

Financial Information · 第 207 页
公司的解释、律师意见及原文页码定位:在 Matters 中查看

Tell us